A Phase 2 Multicenter Single-arm Open-label Study to Evaluate the Activity Safety and Pharmacokinetics of Lenalidomide (Revlimid?) in Pediatric Subjects From 1 to = 18 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia.
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to investigate the use of lenalidomide for treatment for acute myeloid leukemia in children or adolescents.
Description
The purpose of this study is to determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory AML measured by morphological complete response defined as either a CR or CRi within the first 4 cycles of treatment.
Details
| Condition | acute myeloid leukemia |
|---|---|
| Age | 1years - 18years |
| Clinical Study Identifier | TX5551 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.